Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

Ferdinand W N M Wit, Remko Van Leeuwen, Gerrit Jan Weverling, Suzanne Jurriaans, Klaas Nauta, Radjin Steingrover, Johan Schuijtemaker, Xander Eyssen, David Fortuin, Marjan Weeda, Frank De Wolf, Peter Reiss, Sven A. Danner, Joep M A Lange

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

The outcome and predictors of virologic treatment failure of highly active antiretroviral therapy (HAART) were determined for 271 human immunodeficiency virus (HIV)-infected protease inhibitor-naive persons. During a follow-up of 48 weeks after the initiation of HAART, 6.3% of patients experienced at least one new AIDS-defining event, and 3.0% died. Virologic treatment failure occurred in 40% (indinavir, 27%; ritonavir, 30%; saquinavir, 59%; ritonavir plus saquinavir, 32%; χ2, P = .001). Risk factors for treatment failure were baseline plasma HIV-1 RNA (odds ratio [OR], 1.70 per log10 copies increase in plasma HIV-1 RNA), baseline CD4 cell count (OR, 1.35 per 100 CD4 cells/mm3 decrease), and use of saquinavir versus other protease inhibitors (OR, 3.21). During the first year of treatment, 53% of all patients changed (part of) their original HAART regimen at least once. This was significantly more frequent for regimens containing saquinavir (62%; 27% for virologic failure) or ritonavir (64%; 55% for intolerance) as single protease inhibitor.

Original languageEnglish (US)
Pages (from-to)790-798
Number of pages9
JournalJournal of Infectious Diseases
Volume179
Issue number4
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Saquinavir
Highly Active Antiretroviral Therapy
Ritonavir
HIV-1
Protease Inhibitors
Treatment Failure
Odds Ratio
RNA
Indinavir
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
HIV

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Outcome and predictors of failure of highly active antiretroviral therapy : One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. / Wit, Ferdinand W N M; Van Leeuwen, Remko; Weverling, Gerrit Jan; Jurriaans, Suzanne; Nauta, Klaas; Steingrover, Radjin; Schuijtemaker, Johan; Eyssen, Xander; Fortuin, David; Weeda, Marjan; De Wolf, Frank; Reiss, Peter; Danner, Sven A.; Lange, Joep M A.

In: Journal of Infectious Diseases, Vol. 179, No. 4, 1999, p. 790-798.

Research output: Contribution to journalArticle

Wit, FWNM, Van Leeuwen, R, Weverling, GJ, Jurriaans, S, Nauta, K, Steingrover, R, Schuijtemaker, J, Eyssen, X, Fortuin, D, Weeda, M, De Wolf, F, Reiss, P, Danner, SA & Lange, JMA 1999, 'Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons', Journal of Infectious Diseases, vol. 179, no. 4, pp. 790-798. https://doi.org/10.1086/314675
Wit, Ferdinand W N M ; Van Leeuwen, Remko ; Weverling, Gerrit Jan ; Jurriaans, Suzanne ; Nauta, Klaas ; Steingrover, Radjin ; Schuijtemaker, Johan ; Eyssen, Xander ; Fortuin, David ; Weeda, Marjan ; De Wolf, Frank ; Reiss, Peter ; Danner, Sven A. ; Lange, Joep M A. / Outcome and predictors of failure of highly active antiretroviral therapy : One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. In: Journal of Infectious Diseases. 1999 ; Vol. 179, No. 4. pp. 790-798.
@article{b954fdcd08714eea81b3d3b19dd37dfe,
title = "Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons",
abstract = "The outcome and predictors of virologic treatment failure of highly active antiretroviral therapy (HAART) were determined for 271 human immunodeficiency virus (HIV)-infected protease inhibitor-naive persons. During a follow-up of 48 weeks after the initiation of HAART, 6.3{\%} of patients experienced at least one new AIDS-defining event, and 3.0{\%} died. Virologic treatment failure occurred in 40{\%} (indinavir, 27{\%}; ritonavir, 30{\%}; saquinavir, 59{\%}; ritonavir plus saquinavir, 32{\%}; χ2, P = .001). Risk factors for treatment failure were baseline plasma HIV-1 RNA (odds ratio [OR], 1.70 per log10 copies increase in plasma HIV-1 RNA), baseline CD4 cell count (OR, 1.35 per 100 CD4 cells/mm3 decrease), and use of saquinavir versus other protease inhibitors (OR, 3.21). During the first year of treatment, 53{\%} of all patients changed (part of) their original HAART regimen at least once. This was significantly more frequent for regimens containing saquinavir (62{\%}; 27{\%} for virologic failure) or ritonavir (64{\%}; 55{\%} for intolerance) as single protease inhibitor.",
author = "Wit, {Ferdinand W N M} and {Van Leeuwen}, Remko and Weverling, {Gerrit Jan} and Suzanne Jurriaans and Klaas Nauta and Radjin Steingrover and Johan Schuijtemaker and Xander Eyssen and David Fortuin and Marjan Weeda and {De Wolf}, Frank and Peter Reiss and Danner, {Sven A.} and Lange, {Joep M A}",
year = "1999",
doi = "10.1086/314675",
language = "English (US)",
volume = "179",
pages = "790--798",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Outcome and predictors of failure of highly active antiretroviral therapy

T2 - One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

AU - Wit, Ferdinand W N M

AU - Van Leeuwen, Remko

AU - Weverling, Gerrit Jan

AU - Jurriaans, Suzanne

AU - Nauta, Klaas

AU - Steingrover, Radjin

AU - Schuijtemaker, Johan

AU - Eyssen, Xander

AU - Fortuin, David

AU - Weeda, Marjan

AU - De Wolf, Frank

AU - Reiss, Peter

AU - Danner, Sven A.

AU - Lange, Joep M A

PY - 1999

Y1 - 1999

N2 - The outcome and predictors of virologic treatment failure of highly active antiretroviral therapy (HAART) were determined for 271 human immunodeficiency virus (HIV)-infected protease inhibitor-naive persons. During a follow-up of 48 weeks after the initiation of HAART, 6.3% of patients experienced at least one new AIDS-defining event, and 3.0% died. Virologic treatment failure occurred in 40% (indinavir, 27%; ritonavir, 30%; saquinavir, 59%; ritonavir plus saquinavir, 32%; χ2, P = .001). Risk factors for treatment failure were baseline plasma HIV-1 RNA (odds ratio [OR], 1.70 per log10 copies increase in plasma HIV-1 RNA), baseline CD4 cell count (OR, 1.35 per 100 CD4 cells/mm3 decrease), and use of saquinavir versus other protease inhibitors (OR, 3.21). During the first year of treatment, 53% of all patients changed (part of) their original HAART regimen at least once. This was significantly more frequent for regimens containing saquinavir (62%; 27% for virologic failure) or ritonavir (64%; 55% for intolerance) as single protease inhibitor.

AB - The outcome and predictors of virologic treatment failure of highly active antiretroviral therapy (HAART) were determined for 271 human immunodeficiency virus (HIV)-infected protease inhibitor-naive persons. During a follow-up of 48 weeks after the initiation of HAART, 6.3% of patients experienced at least one new AIDS-defining event, and 3.0% died. Virologic treatment failure occurred in 40% (indinavir, 27%; ritonavir, 30%; saquinavir, 59%; ritonavir plus saquinavir, 32%; χ2, P = .001). Risk factors for treatment failure were baseline plasma HIV-1 RNA (odds ratio [OR], 1.70 per log10 copies increase in plasma HIV-1 RNA), baseline CD4 cell count (OR, 1.35 per 100 CD4 cells/mm3 decrease), and use of saquinavir versus other protease inhibitors (OR, 3.21). During the first year of treatment, 53% of all patients changed (part of) their original HAART regimen at least once. This was significantly more frequent for regimens containing saquinavir (62%; 27% for virologic failure) or ritonavir (64%; 55% for intolerance) as single protease inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=0004674209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0004674209&partnerID=8YFLogxK

U2 - 10.1086/314675

DO - 10.1086/314675

M3 - Article

C2 - 10068573

AN - SCOPUS:0004674209

VL - 179

SP - 790

EP - 798

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -